Real-world evidence (RWE) offer the potential to help inform and potentially improve Healthcare Decisions.

 

Real-world evidence (RWE) is clinical evidence gathered via real-world data (RWD) analysis on a medical product’s use and potential benefits or risks. RWE can be produced through various study designs or analyses, including but not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). For example, the role of RWE in drug development is expanding as RWE studies are significantly less costly and time-consuming than RCTs, providing easier access to long-term effectiveness data and helping overcome some of the feasibility barriers of running RCTs. RWE is regularly utilized in the drug development & approval process to inform aspects of drug development, such as the natural history and epidemiology of a disease, and to provide data on treatment pathways and comparator interventions in clinical practice.

According to a new market research report titled “RWE Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, integrated], Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) — Global Forecast to 2028”, published by Meticulous Research^®, the real-world evidence solutions market is expected to grow at a CAGR of 11.8% from 2021–2028 to reach $4.4 billion by 2028.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=4954?utm_source=Blog&utm_medium=Social&utm_campaign=Product&utm_content=22-12-2021

Real-world evidence (RWE) is clinical evidence gathered via Real World Data (RWD) analysis on the use and potential benefits or risks of a medical product. RWE can be produced through various study designs or analyses, including but not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). RWE has several applications, including drug development life cycles, shortening development timelines, reducing the costs of clinical trials, and improving the probability of technical and regulatory success. The growth of this market is primarily driven by key factors such as the rapid growth of large data in healthcare, the shift from volume to value-based care, and the rising focus towards personalized healthcare.

Impact of COVID-19 on RWE Solutions Market

The key players operating in the RWE solutions market experienced an initial market shrinkage due to uncertainties associated with the impact of the COVID-19 pandemic. The market shrinkage was mainly due to significant restrictions on travel in many countries, shifting of resources on COVID-19 treatments in healthcare settings, and limited access to hospitals. These factors affected the amount of real-world data generated globally.

However, after the initial shrinkage, real-world evidence (RWE) is set to become the most influential emerging technology to fight against the COVID-19 outbreak. Real-world evidence solutions can provide valuable insights to better understand, monitor, and prepare for the challenges caused by the COVID-19 pandemic. RWD has been used increasingly to map the progression of the disease and to discover vaccines and immediate treatments. Thus, the effectiveness of the use of RWD made a significant impact during the pandemic and continues to play a significant role in the treatment of infected patients.

Quick Buy – RWE Solutions Market Research Report:    https://www.meticulousresearch.com/BuyNowToCheckout/751?utm_source=Blog&utm_medium=Social&utm_campaign=Product&utm_content=22-12-2021

RWE Solutions Market: Future Outlook

The RWE Solutions Market is segmented by component (datasets and consulting services), application (market access & reimbursement/coverage decisions, drug development & approvals, post market surveillance, medical device development & approvals, and other applications), end user (pharmaceutical, biotechnology, and medical device companies, healthcare payers, healthcare providers, and other end users), and geography (North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa).

Based on component, the datasets segment is estimated to account for a larger share of the overall RWE solutions market in 2021. The large share of this segment is mainly attributed to the growing amount of medical data generated in hospitals and the increasing dependence of outcome-based studies on real-world data. EHRs are the most commonly used form of healthcare database that helps in conducting outcome-based studies. EHR data is playing an increasingly vital role in collecting and generating actionable information at the FDA. Governments across the world are undertaking initiatives to increase the adoption of EHR/EMR data. For instance, in September 2020, to digitalize the entire healthcare ecosystem of India, the Ministry of Health and Family Welfare (MoHFW) released a draft policy termed the Health Data Management Policy. However, the consulting services segment is expected to witness the fastest growth rate during the forecast period. Real-world evidence consulting service providers make use of robust real-world datasets generated by conducting prospective/observational studies to offer customized consulting services to generate fit-for-purpose data and insights for their stakeholders instead of providing terabytes of data.

Based on application, the market access & reimbursement/coverage decisions segment is estimated to account for the largest share of the RWE solutions market in 2021. The pharmaceutical, biotech, and medical device industries face unprecedented challenges due to the global economic crisis, COVID-19 pandemic, and concerns about escalating healthcare costs. Due to rising therapy costs, healthcare payers are increasingly focused on evidence of clinical value for making decisions associated with providing coverage. RWE helps provide a means for demonstrating value, ranging from confirming randomized trial benefits in real-world populations to a fuller characterization of resource impacts. RWE is being increasingly considered by both industry and payers. Payers use the data to support coverage decisions, develop guidelines and decision support tools for use in clinical practice, generate estimates of the potential population they cover that could require the treatment, and estimate potential costs and cost offsets. However, the drug development & approvals segment is expected to witness the fastest growth rate during the forecast period.

To gain more insights into the market with a detailed table of content and figures, click here:  https://www.meticulousresearch.com/product/Real-World-Evidence-Solutions-Market-4954?utm_source=Blog&utm_medium=Social&utm_campaign=Product&utm_content=22-12-2021

Based on end user, the pharmaceutical, biotechnology, & medical device companies segment is expected to witness the fastest growth rate during the forecast period. Rising pharmaceutical R&D spending is the major factor attributed to the growth of this segment. The cost of developing a new drug was more than $2,600 million in 2020 compared to $802 million in 2003. This increase in drug development costs reflects various technical, regulatory, and economic challenges pharmaceutical R&D pipelines face. The global R&D spending in 2021 surged by 7.0% ($212 billion) compared to 2020. Real-world evidence helps in understanding real-life clinical practices and actual health outcomes of drugs. It also helps generate broader scientific evidence and commercial insights, valuable for the pharmaceutical industry.

Geographically, North America is estimated to command the largest share of the global RWE solutions market in 2021, followed by Asia-Pacific, Europe, Latin America, and the Middle East & Africa. However, Asia-Pacific region is expected to be the fastest-growing regional market due to growing demand from payers for data that defines the value and effectiveness of medicines, growing demand in conducting real-world studies in drug R&D, and increasing government interest in using real-world studies for regulatory decision-making.

Key companies operating in the global RWE solutions market are IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.) among others.

TOP 10 COMPANIES IN REAL WORLD EVIDENCE (RWE)SOLUTIONS MARKET

Scope of the Report

RWE Solutions Market, by Component

• Datasets
• Disparate Datasets
• EMR/EHR/Clinical Data
• Claims & Billing Data
• Pharmacy Data
• Product/Disease Registries Data
• Other Disparate Datasets
• Integrated Datasets
• Consulting & Analytics

(Note: Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)

RWE Solutions Market, by Application

• Market Access & Reimbursement/Coverage Decisions
• Drug Development & Approvals
• Oncology
• Neurology
• Immunology
• Cardiovascular Diseases
• Other Therapeutic Areas
• Post Market Surveillance
• Medical Device Development & Approvals
• Other Applications

(Note: Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases, Other Applications include regulatory and clinical decision-making)

RWE Solutions Market, by End User

• Pharmaceutical, Biotechnology, and Medical Device Companies
• Healthcare Payers
• Healthcare Providers
• Other End Users

(Note: Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)

RWE Solutions Market, by Geography

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe (RoE)   
• Asia-Pacific (APAC)
• Japan
• China
• India
• South Korea
• Taiwan
• Singapore
• Rest of APAC (RoAPAC)
• Latin America
• Middle East & Africa

Download Free Sample Report Now @  https://www.meticulousresearch.com/download-sample-report/cp_id=4954?utm_source=Blog&utm_medium=Social&utm_campaign=Product&utm_content=22-12-2021

Related Reports:

Healthcare IT Market by Product (EMR, mHealth, PHM, RIS, PACS, RCM, Healthcare Analytics, Telehealth, SCM, HIE), Component (Software, Service), Delivery Mode (Web, Cloud) and End User (Hospital, Payer, Pharmacy, Ambulatory, Homecare)—Global Forecast to 2027

Next-generation Sequencing Services Market by Type (Targeted Sequencing, Exome, RNA-Seq, ChIP Sequencing), Technology (Sequencing by Synthesis, Nanopore, SMRT), Application (Clinical Diagnosis, Biomarker Discovery), & End User - Forecast to 2028

Digital Diabetes Market by Product (SMBG, CGM, Smart Insulin Pump, Smart Insulin Pens, Software, Apps), End User (Home Care, Hospitals and Clinics), and Geography - Global Forecast to 2025

𝐑𝐞𝐚𝐥-𝐖𝐨𝐫𝐥𝐝 𝐄𝐯𝐢𝐝𝐞𝐧𝐜𝐞 (𝐑𝐖𝐄) offer the potential to help inform and potentially improve 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀.

 Real-world evidence (RWE) is clinical evidence gathered via real-world data (RWD) analysis on a medical product’s use and potential benefits or risks. RWE can be produced through various study designs or analyses, including but not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). For example, the role of RWE in drug development is expanding as RWE studies are significantly less costly and time-consuming than RCTs, providing easier access to long-term effectiveness data and helping overcome some of the feasibility barriers of running RCTs. RWE is regularly utilized in the drug development & approval process to inform aspects of drug development, such as the natural history and epidemiology of a disease, and to provide data on treatment pathways and comparator interventions in clinical practice.

According to a new market research report titled “RWE Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, Integrated], Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) — Global Forecast to 2028”, published by Meticulous Research^®, the real-world evidence solutions market is expected to grow at a CAGR of 11.8% from 2021–2028 to reach $4.4 billion by 2028.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=4954?utm_source=Article&utm_medium=Social&utm_campaign=Product&utm_content=15-12-2021

Real-world evidence (RWE) is clinical evidence gathered via Real World Data (RWD) analysis on the use and potential benefits or risks of a medical product. RWE can be produced through various study designs or analyses, including but not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). RWE has several applications, including drug development life cycles, shortening development timelines, reducing the costs of clinical trials, and improving the probability of technical and regulatory success. The growth of this market is primarily driven by key factors such as the rapid growth of large data in healthcare, the shift from volume to value-based care, and the rising focus towards personalized healthcare.

Impact of COVID-19 on RWE Solutions Market

The key players operating in the RWE solutions market experienced an initial market shrinkage due to uncertainties associated with the impact of the COVID-19 pandemic. The market shrinkage was mainly due to significant restrictions on travel in many countries, shifting of resources on COVID-19 treatments in healthcare settings, and limited access to hospitals. These factors affected the amount of real-world data generated globally.

However, after the initial shrinkage, real-world evidence (RWE) is set to become the most influential emerging technology to fight against the COVID-19 outbreak. Real-world evidence solutions can provide valuable insights to better understand, monitor, and prepare for the challenges caused by the COVID-19 pandemic. RWD has been used increasingly to map the progression of the disease and to discover vaccines and immediate treatments. Thus, the effectiveness of the use of RWD made a significant impact during the pandemic and continues to play a significant role in the treatment of infected patients.

Quick Buy – RWE Solutions Market Research Report: https://www.meticulousresearch.com/Checkout/98458809?utm_source=Article&utm_medium=Social&utm_campaign=Product&utm_content=15-12-2021

RWE Solutions Market: Future Outlook

The RWE Solutions Market is segmented by component (datasets and consulting services), application (market access & reimbursement/coverage decisions, drug development & approvals, post market surveillance, medical device development & approvals, and other applications), end user (pharmaceutical, biotechnology, and medical device companies, healthcare payers, healthcare providers, and other end users), and geography (North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa).

Based on component, the datasets segment is estimated to account for a larger share of the overall RWE solutions market in 2021. The large share of this segment is mainly attributed to the growing amount of medical data generated in hospitals and the increasing dependence of outcome-based studies on real-world data. EHRs are the most commonly used form of healthcare database that helps in conducting outcome-based studies. EHR data is playing an increasingly vital role in collecting and generating actionable information at the FDA. Governments across the world are undertaking initiatives to increase the adoption of EHR/EMR data. For instance, in September 2020, to digitalize the entire healthcare ecosystem of India, the Ministry of Health and Family Welfare (MoHFW) released a draft policy termed the Health Data Management Policy. However, the consulting services segment is expected to witness the fastest growth rate during the forecast period. Real-world evidence consulting service providers make use of robust real-world datasets generated by conducting prospective/observational studies to offer customized consulting services to generate fit-for-purpose data and insights for their stakeholders instead of providing terabytes of data.

Based on application, the market access & reimbursement/coverage decisions segment is estimated to account for the largest share of the RWE solutions market in 2021. The pharmaceutical, biotech, and medical device industries face unprecedented challenges due to the global economic crisis, COVID-19 pandemic, and concerns about escalating healthcare costs. Due to rising therapy costs, healthcare payers are increasingly focused on evidence of clinical value for making decisions associated with providing coverage. RWE helps provide a means for demonstrating value, ranging from confirming randomized trial benefits in real-world populations to a fuller characterization of resource impacts. RWE is being increasingly considered by both industry and payers. Payers use the data to support coverage decisions, develop guidelines and decision support tools for use in clinical practice, generate estimates of the potential population they cover that could require the treatment, and estimate potential costs and cost offsets. However, the drug development & approvals segment is expected to witness the fastest growth rate during the forecast period.

To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/Real-World-Evidence-Solutions-Market-4954?utm_source=Article&utm_medium=Social&utm_campaign=Product&utm_content=15-12-2021

Based on end user, the pharmaceutical, biotechnology, & medical device companies segment is expected to witness the fastest growth rate during the forecast period. Rising pharmaceutical R&D spending is the major factor attributed to the growth of this segment. The cost of developing a new drug was more than $2,600 million in 2020 compared to $802 million in 2003. This increase in drug development costs reflects various technical, regulatory, and economic challenges pharmaceutical R&D pipelines face. The global R&D spending in 2021 surged by 7.0% ($212 billion) compared to 2020. Real-world evidence helps in understanding real-life clinical practices and actual health outcomes of drugs. It also helps generate broader scientific evidence and commercial insights, valuable for the pharmaceutical industry.

Geographically, North America is estimated to command the largest share of the global RWE solutions market in 2021, followed by Asia-Pacific, Europe, Latin America, and the Middle East & Africa. However, Asia-Pacific region is expected to be the fastest-growing regional market due to growing demand from payers for data that defines the value and effectiveness of medicines, growing demand in conducting real-world studies in drug R&D, and increasing government interest in using real-world studies for regulatory decision-making.

Key companies operating in the global RWE solutions market are IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.) among others.

TOP 10 COMPANIES IN REAL WORLD EVIDENCE (RWE)SOLUTIONS MARKET

Scope of the Report

RWE Solutions Market, by Component

• Datasets
  • Disparate Datasets
    • EMR/EHR/Clinical Data
    • Claims & Billing Data
    • Pharmacy Data
    • Product/Disease Registries Data
    • Other Disparate Datasets
  • Integrated Datasets
• Consulting & Analytics

(Note: Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)

RWE Solutions Market, by Application

• Market Access & Reimbursement/Coverage Decisions
• Drug Development & Approvals
  • Oncology
  • Neurology
  • Immunology
  • Cardiovascular Diseases
  • Other Therapeutic Areas
• Post Market Surveillance
• Medical Device Development & Approvals
• Other Applications

(Note: Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases, Other Applications include regulatory and clinical decision-making)

RWE Solutions Market, by End User

• Pharmaceutical, Biotechnology, and Medical Device Companies
• Healthcare Payers
• Healthcare Providers
• Other End Users

(Note: Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)

RWE Solutions Market, by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe (RoE)   
• Asia-Pacific (APAC)
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Singapore
  • Rest of APAC (RoAPAC)
• Latin America
• Middle East & Africa

Download Free Sample Report Now @   https://www.meticulousresearch.com/download-sample-report/cp_id=4954?utm_source=Article&utm_medium=Social&utm_campaign=Product&utm_content=15-12-2021

 

Related Reports:

Healthcare IT Market by Product (EMR, mHealth, PHM, RIS, PACS, RCM, Healthcare Analytics, Telehealth, SCM, HIE), Component (Software, Service), Delivery Mode (Web, Cloud) and End User (Hospital, Payer, Pharmacy, Ambulatory, Homecare)—Global Forecast to 2027

 

Future Outlook: Real-World Evidence (RWE) Solutions Market to Witness Lucrative Growth during the Forecast Period (2019-2024)

A report into the projected growth of the current Real-World Evidence (RWE) solutions market by Meticulous Research has produced lucrative forecasts for the industry. By 2024, it’s expected to have grown at a compound annual growth rate (CAGR) of 15.0%, reaching $1.64 billion.

Future Outlook: Real-World Evidence (RWE) Solutions Market to Witness Lucrative Growth during the Forecast Period (2019-2024)

In a report published today, Meticulous Research® has stated that the size of the global Real-World Evidence (RWE) solutions market will reach an impressive $1.64 billion by 2024.

The researchers suggest that the growth of Real-World Evidence (RWE) solutions market will be driven by factors including the rising geriatric population and burden of chronic diseases, shift towards value-based care, increasing R&D expenditure by the life sciences industry, delays in drug development and the subsequent increase in development costs, and expanding use of RWE for regulatory decision making.

The report states that data sets currently account for the largest share of the total market and is expected to grow at a CAGR of 13.8% from 2019 to 2024. Meticulous Research® identified as to why this segment will continue dominating over real-world evidence services: “Due to increasing need for additional insights on epidemiology, compliance, adherence and costs in a realistic environment; growing amount of medical data generated in hospitals; increasing dependence of outcome-based studies on real-world data; and rising demand for information by the payers, regulatory bodies and providers regarding drug safety.”

Based on application, drug development and approvals commanded the largest share in 2018 owing to significant demand of RWD and RWE to accelerate drug discovery and development, increasing investment by biopharmaceutical companies in R&D, and growing inclination of regulatory bodies towards RWE. However, adoption of RWE for market access and reimbursement/coverage decisions is expected to witness fastest growth.

Pharmaceutical, biotechnology & medical device companies were the leading adopters of real-world evidence solutions in 2018 and are also expected to register fastest growth during the forecast period. This is attributed to the increasing importance of RWE studies in drug development and approvals, growing focus to avoid costly drug recalls, increasing need to assess drug performance in real-world settings, and growing emphasis on drug safety and post-market surveillance.

The report further speculates that North America is currently home for most of the real-world evidence solutions providers and is the leading adopter of RWD and RWE. The largest as well as fastest growth of this region is supported by significant availability of real-world data sets, growing focus on value-based care, rising R&D expenditure by the biopharma companies, greater emphasis on early drug/device development and approvals, stringent regulations for drug approvals, and favorable government policies (implementation of 21st Century Cures Act (December 2016) and FDA’s new 2019 strategic Framework for RWE (December 2018) in the U.S).

Real World Evidence (RWE) Solutions Market by Component (RWD, EMR, Claim, Patient Registry, Pharmacy, Service), Application (Oncology, CVD, Neuro, Infection, Regulatory), End User (Pharma, Biotech, Medical Devices, Payers, Healthcare) - Global Forecast to 2024

The key players operating in the global real-world evidence (REW) solutions market are Anthem, Inc., Clinigen Group plc, Cognizant, IBM Corporation, ICON plc, IQVIA, Optum,Inc., Oracle Corporation, PAREXEL International Corporation, PerkinElmer Inc., Pharmaceutical Product Development, LLC., SAS Institute Inc., and Syneos Health among others.

Key questions answered in the report- 

Shift towards value-based care & Growing focus on personalized health care to drive the adoption of RWE Solutions 

• How does the penetration of RWE Solutions in Drug Development & Approvals is differ from that in Market Access & Reimbursement/Coverage Decisions applications?
• What impact does this have on the adoption of RWE Solutions to other conventional technologies for various application?

Pharmaceutical, biotechnology and medical device companies account for largest proportion of all End-user of RWE solution globally 

• What factors contribute to the frequent usage of RWE solution for Pharmaceutical, biotechnology and medical device?
• Conversely, which geographic segment is expected to experience the fastest growth for Pharmaceutical, biotechnology and medical device?

The North American RWE solution market favours both larger and local manufacturers that compete in multiple segments 

• Who are the top competitors in this market and what strategies do they employ to gain shares?
• What is driving growth and which market segments have the most potential for revenue expansion during the forecast period?
• What strategies must companies adopt who are looking to enter this market and compete effectively?
• What are the major drivers, restraints, opportunities, and challenges in the global RWE solution market?
• Who are the major players in various countries and what share of the market do they hold?
• What are the geographical trends and high growth regions/ countries?

Recent new service launches, acquisitions, collaborations, partnerships, and expansions have taken place in the RWE solution space. 

• What companies have recently merged/acquired and how will these unions affect the competitive landscape of the RWE solution space?
• What companies have created partnerships and how will these partnerships promote a competitive advantage?
• Who are the major players in the global RWE solution market and what share of the market do they hold?
• What are the local emerging players in the global RWE solution market and how do they compete with the global players?

Request TOC and Sample Pages @

https://www.meticulousresearch.com/request-sample-report/cp_id=4954

About Meticulous Research®

Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicated market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth. Meticulous Research® produces global reports and custom studies for North America, Europe, Latin America, Asia-Pacific, and the Middle East and Africa regions. These reports are used by our clients for marketing and strategic planning in various sectors.

Contact Us:

Meticulous Research®

Email- sales@meticulousresearch.com

Contact Sales- +1-646-781-8004

Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

Next Generation Sequencing (NGS) Services Market - Global Opportunity Analysis and Industry Forecast (2018-2023)

Global NGS services market has shown strong growth pattern in recent year’s majorly due plummeting cost of sequencing, need of skilled professionals for efficient NGS sample preparation and analysis, technological advancements in NGS services, increase in genome mapping programs, high cost of sequencing infrastructures are expected to boost the demand for NGS services across the globe. However, installation of in-house sequencing facilities in hospitals and universities for genome testing may obstruct the growth of NGS services to some extent.

Meticulous Research® in its latest publication on global NGS services market states that the global NGS services market will increase at a CAGR of 20.1% from 2018 to 2023 to reach USD 2,921.4 million by 2023. The recent advances in the field of genomics research over the past years have led to substantial reduction in the cost of genome sequencing. The NGS technology has reduced the cost and increased the speed of DNA sequencing significantly.

Meticulous Research states that “In genomics research field, sequencing is being applied not only to assemble genomes and to investigate the genetic basis of human diseases, but also to understand the diverse nature of reproductive medicine, oncology and infectious diseases. The cheaper genome sequencing could revolutionize healthcare, allowing doctors to prescribe individualized treatment options for patients. Also, this would enable faster progress in clinical research, pushing research for cancer and other genetically linked diseases forward”.

The cost of sequencing closely followed a Moore’s law trajectory over the years before 2008; however, the introduction of NGS technologies caused costs to fall faster than would be expected by Moore’s law. In 2003, the first time the human genome was sequenced for a price of $2.7 billion. Later, the price of sequencing an average human genome declined from about USD10million to a few thousands in just 6 years of duration (2007-2013). Further to this declining price trend, in January 2017, Illumina debuted a new sequencing machine, the NovaSeq (NovaSeq 5000 and NovaSeq 6000), which has ability to sequence an entire genome for less than USD 100 in fewer than 60 minutes.

The report provides meticulous analysis of global NGS services market by segmenting it on the basis of service type (targeted sequencing, rna sequencing, exome sequencing, de novo sequencing, chip-sequencing, whole genome sequencing, methyl sequencing, and other services), technology [sequencing by synthesis (sbs), ion semiconductor sequencing (ios), single molecule real time sequencing (smrt), nanopore sequencing, and true single molecule sequencing (tsms)], application (diagnostics, drug discovery, biomarker discovery, agriculture & animal research, and other applications), end user (academic& research institutes, pharmaceuticals & biotechnology industry, hospitals & clinics and other end users), and geography.

Check Discount before buying the report @ https://www.meticulousresearch.com/request-discount/cp_id=3875

The key players analyzed in the global NGS services market are Illumina, Inc. (U.S.), Qiagen N.V. (The Netherlands), PerkinElmer, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), GATC Biotech AG (Germany), Macrogen, Inc. (South Korea), Genotypic Technology Pvt. Ltd. (India), GENEWIZ, Inc. (U.S.), Beijing Genomics Institute (BGI) (China), SciGenom Labs Pvt. Ltd. (India), MedGenome (India), DNA Link, Inc. (South Korea), Otogenetics Corporation (U.S.), Novogene Corporation (China), LGC Limited (U.K.), CD Genomics (U.S.), and SeqLL, LLC (U.S.)

Key questions answered in the report-

Growing genomics research in academic and research institutes and outsourcing of genome testing in biopharmaceutical & biotechnology industry to drive the adoption of NGS services

-How does the penetration of NGS services in biopharmaceutical industry differ from that in diagnostics and biomarker discovery applications?
-What impact does this have on the adoption of NGS services in comparison to other conventional technologies for detection of genetic mutations?

Agriculture & animal research account for a relatively small proportion of all applications of NGS services globally
-What factors contribute to the infrequent usage of NGS services for agriculture & animal research?
-Conversely, which geographic segment is expected to experience the fastest growth for agriculture & animal research?

The North American NGS services market favors both larger and local manufacturers that compete in multiple segments
-Who are the top competitors in this market and what strategies do they employ to gain shares?
-What is driving growth and which market segments have the most potential for revenue expansion during the forecast period?
-What strategies must companies adopt who are looking to enter this market and compete effectively?
-What are the major drivers, restraints, opportunities, and challenges in the global NGS services market?
-Who are the major players in various countries and what share of the market do they hold?
-What are the geographical trends and high growth regions/ countries?

Recent new service launches, acquisitions, collaborations, partnerships, and expansions have taken place in the NGS services space.
-What companies have recently merged/acquired and how will these unions affect the competitive landscape of the NGS services space?
-What companies have created partnerships and how will these partnerships promote a competitive advantage?
-Who are the major players in the global NGS services market and what share of the market do they hold?
-What are the local emerging players in the global NGS services market and how do they compete with the global players?

Download free sample report and gain crucial industry insights @ https://www.meticulousresearch.com/download-sample-report/cp_id=3875

About Meticulous Research®

Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, with the help of its unique research methodologies, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa regions.

Contact – 
Meticulous Market Research Pvt. Ltd.
Khushal Bombe
sales@meticulousresearch.com

Office No-402, 4th Floor, 
Pushpak Business Hub, 
Wakad, Pimpri-Chinchwad, 411057 India.

Direct Lines :
+1-646-781-8004 (North America)
+91 744-7780008 (Asia-Pacific)